Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
Authors
Keywords
Ovarian cancer treatment, Solid lipid particles, Drug delivery and cancer, Drug targeting and cancer, LDL receptors
Journal
MEDICAL ONCOLOGY
Volume 34, Issue 9, Pages -
Publisher
Springer Nature
Online
2017-07-29
DOI
10.1007/s12032-017-1009-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents
- (2017) Raul C Maranhão et al. Expert Opinion on Drug Delivery
- Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella
- (2017) Danielle Cristinne Azevedo Feio et al. International Journal of Nanomedicine
- Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape
- (2016) Claudia Zylberberg et al. DRUG DELIVERY
- Olaparib for the treatment of epithelial ovarian cancer
- (2016) Jennifer McLachlan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10
- (2015) Sook Hee Hong et al. GYNECOLOGIC ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Lipid-coated polymeric nanoparticles for cancer drug delivery
- (2015) Sangeetha Krishnamurthy et al. Biomaterials Science
- Albumin and its application in drug delivery
- (2014) Darrell Sleep Expert Opinion on Drug Delivery
- The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
- (2014) Ajit Gubbi et al. Expert Review of Anticancer Therapy
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
- (2012) Ilan Bruchim et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study
- (2008) Luís A. Pires et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
- (2008) Paul Sabbatini et al. GYNECOLOGIC ONCOLOGY
- Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy
- (2008) Shin Nishio et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search